Should You Buy Canopy Growth (TSX:WEED) Ahead of Earnings?

Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) has made big moves this spring, but there is anxiety in the sector ahead of its next earnings report.

| More on:
edit Business accounting concept, Business man using calculator with computer laptop, budget and loan paper in office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canopy Growth (TSX:WEED)(NYSE:CGC) is the largest cannabis company by market cap on the TSX. In early April the company joined the S&P/TSX 60 Index, becoming the first company in the fledgling cannabis sector to do so. Canopy Growth stock gained significant momentum in April after this announcement, but it has struggled in the month of May.

Shares have dropped 18% month-over-month as of close on May 29. In mid-April, I warned investors that volatility would likely catch up to the cannabis sector before the spring was finished. Still, Canopy Growth stock has climbed 56% in 2019 so far.

Is Canopy Growth worth buying ahead of its fourth quarter fiscal 2019 results? It is expected to release its next batch of earnings on June 26. Several of the top producers have released earnings that have disappointed in the spring. Cannabis sales softened to open the calendar year as supply has continued to weigh on retailers.

Most of the top producers will have ramped up production to much larger levels by the end of the year, but in the near term the industry is still experiencing growing pains.

In its third quarter fiscal 2019 results, Canopy Growth saw revenue surge 282% year-over-year to $83 million and the company sold 10,102 kilograms of cannabis. Similar to its peers, Canopy is working feverishly to ramp up production in order to fill demand domestically and for its expanding global footprint.

In late May, the Government of Canada gave approval to Les Serres Vert Cannabis, a subsidiary of Canopy Growth, to begin cannabis production. It boasts a 700,000 square foot operating space in Mirabel, Quebec; nearly 200,000 square feet were not being used.

The most exciting development at Canopy in recent weeks was its deal with Acreage, a U.S.-based cannabis company. As it stands today, shareholders with 91% of vote shares at Acreage are poised to approve the acquisition.

Canopy CEO Bruce Linton said the language of the deal affords Canopy some flexibility, as the debate over recreational cannabis still rages south of the border. The needle is pointing in the direction of more leniency on a federal level going forward, and Acreage will give Canopy valuable access to an enormous market.

Canopy Growth stock was up 1.14% in early afternoon trading on May 30. Like many top producers in this young sector, Canopy Growth boasts a high valuation. The stock had an RSI of 40 as of this writing, putting it in neutral territory as far as this technical indicator is concerned.

Turbulence in the broader market should concern investors as we move into the summer months. In the sector’s short history, broader volatility has proven to sweep up cannabis stocks.

Canopy Growth and other top producers challenged 52-week lows in the late 2018 stock market rout. There’s a lot to like about Canopy Growth going forward, especially after its Acreage move. However, the stock is still too pricey for me ahead of its next earnings report.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »